Who founded Nabla Bio?

Nabla Bio was founded by Surge Biswas, Frances Anastassacos in 2020.

Who are Nabla Bio's investors?

Nabla Bio's investors include Cantos Ventures, Fifty Years, Petri, Pillar VC, Radical Ventures, Sparta Group, Y Combinator, Zetta Venture Partners and 5 more.

How much funding has Nabla Bio raised?

Nabla Bio has disclosed $37M raised across 2 of its 3 known rounds.

Where is Nabla Bio headquartered?

Nabla Bio is headquartered in Boston, US.

Nabla Bio

YC S20

Boston, US · Founded 2020 · 8 employees · 13 known investors

Find your way into Nabla Bio

Paths you didn't know you had: your email and LinkedIn already hold routes to the Nabla Bio team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Nabla is a drug development company that applies design discipline and scientific rigor to the development of new medicines. The company focuses on making drug development more systematic and iterative, serving the pharmaceutical and biotech industry.

Also known as Inc.

AI & Machine Learning Biotech Deep Tech Healthtech AI-powered Drug DiscoveryUnited States of AmericaAmerica / CanadaPartly Remote

Founders & leadership· Y Combinator alumni (S20)

Nabla Bio was founded in 2020 by Surge Biswas and Frances Anastassacos.

Surge Biswas Co-founder & CEOSurge Biswas has over a decade of experience applying synthetic biology and machine learning to biological engineering. He recently earned a PhD from Harvard University under George Church.

Frances Anastassacos CofounderFrances Anastassacos holds a PhD in Biological Sciences from Harvard University (2019) and has eight years of experience in synthetic biology and chemistry applied to biological systems. She has worked in biotech venture capital before founding Nabla Bio.

George M. ChurchFounder

Surge Biswas Frances AnastassacosFounder

Investors · 13

Cantos Ventureslisted by Cantos VenturesSan Francisco · $400K – $1.5M

How we know: Cantos Ventures's portfolio page · the VCSheet dataset · Y Combinator's founder network · Not right? Tell us

Fifty Yearslisted by Fifty YearsSan Francisco · $250K – $2M

How we know: Fifty Years's portfolio page · funding news · the VCSheet dataset · Y Combinator's founder network · Not right? Tell us

Petrilisted by PetriBoston · $100K – $6M

How we know: Petri's portfolio page · Y Combinator's founder network · Not right? Tell us

Pillar VClisted by Pillar VCBoston · $50K – $4M

How we know: Pillar VC's portfolio page · Not right? Tell us

Radical Ventureslisted by Radical VenturesToronto · $1M – $25M

How we know: Radical Ventures's portfolio page · a partner's Signal profile · funding news · biopharmaapac.com · open dataset · 5k.vc investor directory · Y Combinator's founder network · Not right? Tell us

Sparta Grouplisted by Sparta Group

Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · open dataset · 5k.vc investor directory · Not right? Tell us

Zetta Venture Partnerslisted by Zetta Venture PartnersSan Francisco · $1M – $5M

How we know: Zetta Venture Partners's portfolio page · a partner's Signal profile · funding news · list23.com · the VCSheet dataset · Y Combinator's founder network · Not right? Tell us

Boom Capitalreported

How we know: Y Combinator's founder network · open dataset · 5k.vc investor directory · Not right? Tell us

Boom Capital VenturesreportedSan Francisco · $50K – $300Kvia Celestine Schnugg · inferred

How we know: the VCSheet dataset · Not right? Tell us

BraidwellreportedStamford

How we know: Y Combinator's founder network · Not right? Tell us

Khosla VenturesreportedMenlo Park · $100K – $20M

How we know: funding news · list23.com · Y Combinator's founder network · Not right? Tell us

Takeda VenturesreportedCambridge · $1M – $5M

How we know: Y Combinator's founder network · Not right? Tell us

Funding

SEC filings, press & company announcements

$37M disclosed across 2 of 3 rounds · 2021–2024

$26MSeries AMay 2024 · 3 sources
Radical Ventures (lead), Khosla Ventures, Zetta Venture Partners
Source ↗
$11Mseed fundingDec 2021 · 2 sources
Khosla Ventures, Zetta Venture Partners
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 7

Numerion LabsNumerion combines drug discovery expertise with machine learning and computational chemistry. The company applies AI to drug development.

QvinQvin develops the Q-Pad, an FDA-cleared diagnostic menstrual pad that collects menstrual blood samples for non-invasive health monitoring and disease diagnosis. The company uses biomarker analysis from menstrual fluid to serve healthcare organizations and diagnostic platforms in women's health diagnostics.

MacromoltekMacromoltek provides computational modeling and AI-driven antibody design services to biotech and pharmaceutical companies, accelerating the discovery and optimization of therapeutic antibodies. The platform reduces time-to-market and increases the probability of clinical success in drug development.

Reverie LabsReverie Labs develops cancer treatments designed to cross the blood-brain barrier and treat tumors in the central nervous system.

Day One BiopharmaceuticalsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.

Triana BioTRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer. The company applies a target-first molecular glue discovery platform to pursue disease targets previously considered undruggable.

Alnylam PharmaceuticalsAlnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.

Companies working in the same space as Nabla Bio.

Legal entities · 1

corporate structure

Nabla Bio, Inc.

In the news

Nabla Bio Secures $26M Series A Fundingfinsmes.com · May 2024

Frequently asked questions

What does Nabla Bio do?: Nabla is a drug development company that applies design discipline and scientific rigor to the development of new medicines. The company focuses on making drug development more systematic and iterative, serving the pharmaceutical and biotech industry.
Who founded Nabla Bio?: Nabla Bio was founded by Surge Biswas, Frances Anastassacos in 2020.
Who are Nabla Bio's investors?: Nabla Bio's investors include Cantos Ventures, Fifty Years, Petri, Pillar VC, Radical Ventures, Sparta Group, Y Combinator, Zetta Venture Partners and 5 more.
How much funding has Nabla Bio raised?: Nabla Bio has disclosed $37M raised across 2 of its 3 known rounds.
Where is Nabla Bio headquartered?: Nabla Bio is headquartered in Boston, US.